- Home
- XGN vs MRSN Comparison
XGN vs MRSN Comparison
Compare XGN & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- MRSN
- Stock Information
- Founded
- XGN 2002
- MRSN 2001
- Country
- XGN United States
- MRSN United States
- Employees
- XGN N/A
- MRSN N/A
- Industry
- XGN Medical Specialities
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- XGN Health Care
- MRSN Health Care
- Exchange
- XGN Nasdaq
- MRSN Nasdaq
- Market Cap
- XGN N/A
- MRSN 71.9M
- IPO Year
- XGN 2019
- MRSN 2017
- Fundamental
- Price
- XGN $3.84
- MRSN $0.38
- Analyst Decision
- XGN Strong Buy
- MRSN Buy
- Analyst Count
- XGN 2
- MRSN 3
- Target Price
- XGN $7.50
- MRSN $4.00
- AVG Volume (30 Days)
- XGN 101.8K
- MRSN 3.2M
- Earning Date
- XGN 03-11-2025
- MRSN 03-03-2025
- Dividend Yield
- XGN N/A
- MRSN N/A
- EPS Growth
- XGN N/A
- MRSN N/A
- EPS
- XGN N/A
- MRSN N/A
- Revenue
- XGN $55,641,000.00
- MRSN $40,497,000.00
- Revenue This Year
- XGN $20.54
- MRSN N/A
- Revenue Next Year
- XGN $11.86
- MRSN $67.68
- P/E Ratio
- XGN N/A
- MRSN N/A
- Revenue Growth
- XGN 5.89
- MRSN 9.88
- 52 Week Low
- XGN $1.30
- MRSN $0.37
- 52 Week High
- XGN $6.22
- MRSN $4.64
- Technical
- Relative Strength Index (RSI)
- XGN 51.79
- MRSN 32.11
- Support Level
- XGN $3.59
- MRSN $0.41
- Resistance Level
- XGN $4.58
- MRSN $0.45
- Average True Range (ATR)
- XGN 0.52
- MRSN 0.04
- MACD
- XGN 0.09
- MRSN 0.00
- Stochastic Oscillator
- XGN 58.43
- MRSN 7.62
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.